DK3307323T3 - Carbazolderivater til behandling af fibrotiske sygdomme og relaterede symptomer, og tilstande deraf - Google Patents
Carbazolderivater til behandling af fibrotiske sygdomme og relaterede symptomer, og tilstande deraf Download PDFInfo
- Publication number
- DK3307323T3 DK3307323T3 DK16738883.4T DK16738883T DK3307323T3 DK 3307323 T3 DK3307323 T3 DK 3307323T3 DK 16738883 T DK16738883 T DK 16738883T DK 3307323 T3 DK3307323 T3 DK 3307323T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- conditions
- related symptoms
- fibrotic diseases
- carbazole derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562175552P | 2015-06-15 | 2015-06-15 | |
| PCT/IL2016/050624 WO2016203468A1 (en) | 2015-06-15 | 2016-06-14 | Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3307323T3 true DK3307323T3 (da) | 2022-08-15 |
Family
ID=56411840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16738883.4T DK3307323T3 (da) | 2015-06-15 | 2016-06-14 | Carbazolderivater til behandling af fibrotiske sygdomme og relaterede symptomer, og tilstande deraf |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US10632102B2 (da) |
| EP (1) | EP3307323B1 (da) |
| DK (1) | DK3307323T3 (da) |
| ES (1) | ES2924728T3 (da) |
| IL (1) | IL256329B (da) |
| WO (1) | WO2016203468A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016203468A1 (en) | 2015-06-15 | 2016-12-22 | Raziel Therapeutics Ltd. | Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof |
| JP7822308B2 (ja) * | 2019-09-15 | 2026-03-02 | ラジエル セラピューティクス エルティーディー. | 固形腫瘍の処置のための組成物 |
| EP4096653A4 (en) * | 2020-01-28 | 2024-02-28 | Raziel Therapeutics Ltd. | Compositions for the treatment of angiolipoma |
| WO2022234337A2 (en) * | 2021-05-06 | 2022-11-10 | Raziel Therapeutics Ltd. | Crystalline carbazole derivative |
| EP4615443A1 (en) * | 2022-11-07 | 2025-09-17 | Raziel Therapeutics Ltd. | Crystalline carbazole derivative and methods of making thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2590125A (en) | 1952-03-25 | Quaternary-ammonium alkyl | ||
| US2676966A (en) | 1951-04-04 | 1954-04-27 | Searle & Co | Quaternary salts of 9-carbazolealkylamines and 10-acridanalkylamines and methods forpreparing same |
| US2930798A (en) | 1956-08-03 | 1960-03-29 | Clin Byla Ets | 3-alkanoyl 1-tertiary-amino-alkyl indol oximes and production thereof |
| GB832568A (en) | 1956-08-03 | 1960-04-13 | Clin Byla Ets | Heterocyclic compounds and production thereof |
| FR1186832A (fr) | 1956-08-03 | 1959-09-02 | Etablissements Clin-Byla | Composés hétérocycliques dérivés du pyrrol et des benzopyrrols et leur fabrication |
| US3836587A (en) | 1969-11-17 | 1974-09-17 | American Cyanamid Co | Organo phosphonium salts |
| AU5644396A (en) | 1995-05-05 | 1996-11-21 | Novo Nordisk A/S | Novel heterocyclic chemistry |
| PL332896A1 (en) | 1996-10-30 | 1999-10-25 | Lilly Co Eli | Substituted tricyclic compounds |
| US6440961B1 (en) | 1997-10-27 | 2002-08-27 | Dr. Reddy's Research Foundation | Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
| EP1094063A1 (en) | 1999-10-18 | 2001-04-25 | Applied Research Systems ARS Holding N.V. | 9-(Piperazinylalkyl)carbazoles as Bax-modulators |
| GB9925880D0 (en) | 1999-11-01 | 1999-12-29 | British Tech Group Int | B-Carboline derivatives |
| WO2002060867A2 (en) * | 2001-01-29 | 2002-08-08 | Insight Strategy And Marketing Ltd | Carbazole derivatives and their uses as heparanase inhibitors |
| DE60218155D1 (de) | 2001-03-28 | 2007-03-29 | Lilly Co Eli | Substituierte carbazole als inhibitoren von spla2 |
| WO2003027084A1 (en) | 2001-09-25 | 2003-04-03 | Dr. Reddy's Laboratories Ltd. | Improved process for the preparation of optically active phenoxazine derivatives as antidiabetic agents |
| GB0311406D0 (en) | 2003-05-17 | 2003-06-25 | Queen Mary & Westfield College | Substituted phosphonate fluorescent sensors,and use thereof |
| US20070213359A1 (en) | 2005-12-30 | 2007-09-13 | Acadia Pharmaceuticals Inc. | Bicyclic-nitrogen compounds as modulators of ghrelin receptor and uses thereof |
| US8617543B2 (en) | 2007-02-14 | 2013-12-31 | Yolare Pharmaceuticals, LLC | Modified mutant collagenase and its use in fat melting and in scar reduction |
| US20090317372A1 (en) | 2008-06-20 | 2009-12-24 | Zoltan Kiss | Small molecules for the reduction of high blood glucose level |
| UA107652C2 (en) | 2008-10-06 | 2015-02-10 | Incuron Llc | Carbazole compounds and therapeutic uses of the compounds |
| US8362277B2 (en) | 2009-01-09 | 2013-01-29 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| JP5766614B2 (ja) | 2009-01-09 | 2015-08-19 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムThe Board Of Regents Of The University Of Texas System | 神経新生促進化合物 |
| AU2011274787B2 (en) | 2010-07-07 | 2016-06-16 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| KR101986272B1 (ko) * | 2011-11-15 | 2019-06-05 | 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. | 삼환식 화합물, 이를 포함하는 조성물 및 그의 용도 |
| AU2014340351B2 (en) | 2013-10-21 | 2020-01-30 | Alevere Medical Corporation | Fused heterocyclic organic compounds, pharmaceutical compositions, and medical uses thereof |
| WO2016020919A1 (en) | 2014-08-07 | 2016-02-11 | Raziel Therapeutics Ltd. | Compositions comprising tricyclic compounds, and uses thereof |
| WO2016203468A1 (en) | 2015-06-15 | 2016-12-22 | Raziel Therapeutics Ltd. | Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof |
| JP7822308B2 (ja) | 2019-09-15 | 2026-03-02 | ラジエル セラピューティクス エルティーディー. | 固形腫瘍の処置のための組成物 |
| EP4096653A4 (en) | 2020-01-28 | 2024-02-28 | Raziel Therapeutics Ltd. | Compositions for the treatment of angiolipoma |
| US20240041827A1 (en) | 2020-09-16 | 2024-02-08 | Raziel Therapeutics Ltd. | Compositions for the treatment of fat related conditions and disorders |
| EP4213835A4 (en) | 2020-09-16 | 2024-10-02 | Raziel Therapeutics Ltd. | COMPOSITIONS AND METHODS FOR TREATING LIPID-RELATED DISORDERS |
| WO2022234337A2 (en) | 2021-05-06 | 2022-11-10 | Raziel Therapeutics Ltd. | Crystalline carbazole derivative |
-
2016
- 2016-06-14 WO PCT/IL2016/050624 patent/WO2016203468A1/en not_active Ceased
- 2016-06-14 EP EP16738883.4A patent/EP3307323B1/en active Active
- 2016-06-14 DK DK16738883.4T patent/DK3307323T3/da active
- 2016-06-14 ES ES16738883T patent/ES2924728T3/es active Active
- 2016-06-14 US US15/736,307 patent/US10632102B2/en active Active
-
2017
- 2017-12-14 IL IL256329A patent/IL256329B/en active IP Right Grant
-
2020
- 2020-03-23 US US16/826,632 patent/US11191748B2/en active Active
-
2021
- 2021-11-01 US US17/516,556 patent/US12097179B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2924728T3 (es) | 2022-10-10 |
| IL256329B (en) | 2021-04-29 |
| US20200222364A1 (en) | 2020-07-16 |
| US20220117935A1 (en) | 2022-04-21 |
| US20180169066A1 (en) | 2018-06-21 |
| US12097179B2 (en) | 2024-09-24 |
| EP3307323A1 (en) | 2018-04-18 |
| IL256329A (en) | 2018-02-28 |
| EP3307323B1 (en) | 2022-07-13 |
| WO2016203468A1 (en) | 2016-12-22 |
| US10632102B2 (en) | 2020-04-28 |
| US11191748B2 (en) | 2021-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269371A (en) | Treatment methods | |
| DK3570844T3 (da) | Azolopyrimidin til behandlingen af kræftrelaterede lidelser | |
| DK3340981T3 (da) | Aryl, heteroaryl og heterocykliske forbindelser til behandling af medicinske forstyrrelser | |
| DK3442580T3 (da) | Fremgangsmåder til behandling af kolestatiske og fibrotiske sygdomme | |
| DK3277815T3 (da) | Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser | |
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| LT3169328T (lt) | Chinolino dariniai, skirti uždegiminių ligų gydymui | |
| DK3789501T3 (da) | Fremgangsmåde til diagnosticering, behandling og forebyggelse af parkinsons sygdom | |
| DK3185876T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| LT3390390T (lt) | Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3204386T3 (da) | Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed | |
| DK3265087T3 (da) | Fremgangsmåde til behandling med tradipitant | |
| DK3294345T3 (da) | Tpp1-formuleringer og fremgangsmåder til behandling af cln2-sygdom | |
| DK3294283T3 (da) | Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens | |
| DK3157531T3 (da) | Fremgangsmåder og sammensætninger til stimulering af det intestinale enteroendokrinesystem til behandling af sygdomme eller tilstande relateret hertil | |
| DK3110446T3 (da) | Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme | |
| DK3389669T3 (da) | Triterpensaponinvarianter, syntesefremgangsmåder og anvendelse deraf | |
| DK3218351T3 (da) | Fremgangsmåde til fremstilling, isolering og oprensning af farmaceutisk anvendelige former af ahu-377 | |
| DK3578562T3 (da) | L-valinatamidbenzoxaborolderivater til behandling af parasitiske sygdomme | |
| DK3722291T3 (da) | Indolinonforbindelser og deres anvendelse i behandlingen af fibrotiske sygdomme | |
| DK3157522T3 (da) | Muskarin-antagonister og kombinationer deraf til behandlingen af luftvejssygdomme i heste | |
| EP3493821A4 (en) | METHOD OF TREATING THE RESPIRATORY TRACT | |
| DK3307323T3 (da) | Carbazolderivater til behandling af fibrotiske sygdomme og relaterede symptomer, og tilstande deraf |